Essential Hypertension Clinical Trial
— RNS by DWPOfficial title:
Feasibility Study Evaluating the Safety and Efficacy of the Renal Stimulation by Direct Wire Pacing, During Renal Denervation Procedure.
Verified date | January 2024 |
Source | Ceric Sàrl |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this feasibility study is to evaluate the safety and efficacy of the Renal Stimulation (RNS) by Direct Wire Pacing, during Renal Denervation (RDN) procedure in patient candidate for renal denervation with the ParadiseTM System. The main questions it aims to answer are: - Is the RNS before RDN a straightforward method, allowing quantification of the renal sympathetic traffic? - Does the RNS increase blood pressure (SBP), and is this increase significantly blunted after RDN? - Does the 3-month 24h SBP decrease correlated with the RNS-induced SBP change before RDN? - Can the difference between RNS-induced SBP rise before and after RDN be used as a procedural endpoint for RDN? Participants will be asked for their agreement to conduct an RNS before and after the RDN. No additional experimental procedure will be added to the standard of care.
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | July 1, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient willing and able to comply with the protocol and has provided written informed consent. - Age =18 - Patient candidate for renal denervation with the ParadiseTM System based on physician's assessment. - Patients affiliated to a social security system Exclusion Criteria: - Patients who meet any of the contraindications listed in the Instructions for Use of ParadiseTM Ultrasound Renal Denervation System will be excluded: - Renal arteries diameter < 3 mm and > 8 mm - Patient with relevant renal artery disease (% diameter stenosis > 30%, aneurysm or fibromuscular disease) - Stented renal artery - Iliac/femoral artery stenosis precluding insertion of the ParadiseTM catheter - Known allergy to contrast medium - Patient with known secondary cause of hypertension - Patient with contraindication to chronic anticoagulation therapy or heparin - Patient with Type 1 diabetes mellitus - Patient with more than one accessory renal artery - Woman currently pregnant or breastfeeding - Patient with other concomitant conditions that may adversely affect the patient or the study outcome - Patient with mental or physical inability to participate in the study - Patient under judicial protection, tutorship, or curatorship |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ceric Sàrl | Electroducer |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | prevalence of occurrence of adverse events | safety of the renal nerves stimulation performed by Direct Wire Pacing technique during renal denervation procedure | Three month after procedure | |
Primary | efficacy on Systolic Blood Pressure change to be measured with a blood pressure monitor | efficacy of the renal nerves stimulation performed by Direct Wire Pacing technique during renal denervation procedure | Three month after procedure | |
Secondary | Impact on Systolic Blood Pressure | Investigate the impact of the renal denervation in the Renal Nerves Stimulation induced Systolic Blood Pressure change. | Three month after procedure | |
Secondary | Systolic Blood Pressure as response prediction tool | Investigate whether Renal Nerves Stimulation induced Systolic Blood Pressure change before Renal Denervation could be a reliable tool to predict mid-term Renal Denervation response | Three month after procedure | |
Secondary | Systolic Blood Pressure variation as response prediction tool | Investigate whether difference in Renal Nerves Stimulation-induced Systolic Blood Pressure change before and after Renal Denervation could be a reliable tool to predict mid-term Renal Denervation | Three month after procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
Completed |
NCT06395194 -
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT06418074 -
Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity
|
N/A | |
Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
Completed |
NCT00139698 -
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|